Table 3.
Analysis of Drug Resistance of Enterobacteriaceae Bacteria
| 271 Cases with K. pneumoniae | 35 Cases with E. coli | |||||||
|---|---|---|---|---|---|---|---|---|
| 18 ESBL+Sensitivity | 18 ESBL+Drug Resistance | 253 ESBL-Sensitivity | 253 ESBL- Drug Resistance | 17 ESBL+Sensitivity | 17 ESBL+Drug Resistance | 18 ESBL- Sensitivity | 18 ESBL-Drug Resistance | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Amikacin | 16 (88.9) | 2 (11.1) | 253 (100.0) | 0 (0.0) | 14 (82.4) | 3 (17.6) | 18 (100.0) | 0 (0.0) |
| Imipenem | 18(100.0) | 0(0.0) | 251 (99.2) | 0 (%) | 15 (88.2) | 1 (5.9) | 16 (88.9) | 2 (11.1) |
| Tigecycline | 18(100.0) | 0(0.0) | 240 (94.9) | 10(3.9) | 17 (100.0) | 0 (0.0) | 18 (100.0) | 0 (0.0) |
| Ertapenem | 18(100.0) | 0(0.0) | 250 (98.8) | 0(0.0) | 15 (88.2) | 2 (11.8) | 16 (88.9) | 2 (11.1) |
| Cefoxitin | 13(72.2) | 5(27.8) | 240 (94.9) | 8(3.2) | 10 (58.8) | 5 (29.4) | 13 (72.2) | 1 (5.6) |
| Piperacillin/Tazobactam | 17(94.4) | 1(5.6) | 250 (98.8) | 2(0.8) | 16 (94.1) | 0 (0.0) | 15 (88.2) | 2 (11.1) |
| Cefoperazone-Sulbactam | 16(88.9) | 2(11.1) | 251 (99.2) | 2(0.8) | 17 (100.0) | 0 (0.0) | 17 (94.4) | 1 (5.6) |
| Cefepime | 17(94.4) | 1(5.6) | 252 (99.6) | 0(0.0) | 12 (70.6) | 5 (29.4) | 16 (88.9) | 2 (11.1) |
| Ceftriaxone | 8(44.4) | 10(55.6) | 249 (98.4) | 4(1.6) | 3 (17.6) | 14 (82.4) | 15 (83.3) | 2 (11.1) |
| Amoxicillin clavulanate | 12(66.7) | 6(33.3) | 250 (98.8) | 1(0.4) | 8 (47.1) | 4 (23.5) | 8 (44.4) | 4 (22.2) |
| Levofloxacin | 14(77.8) | 4(22.2) | 250 (98.8) | 3(11.9) | 5 (29.4) | 12 (70.6) | 11 (61.1) | 6 (33.3) |
| Trimethoprim/Sulfamethoxazole | 13(77.2) | 5(22.8) | 243 (96.0) | 10(3.9) | 2 (11.8) | 15 (88.2) | 9 (50.0) | 9 (50.0) |